Loading
NASDAQHealthcareBiotechnology
Latest quote
$2.92
+$0.06 · +2.10%
Acumen Pharmaceuticals Inc. operates as a biopharmaceutical entity in the clinical development stage, dedicated to discovering and advancing therapeutic solutions for Alzheimer's disease. A key focus for the company involves progressing ACU193, an investigational targeted immunotherapy drug candidate. This particular humanized monoclonal antibody is currently undergoing initial human testing in Phase I clinical trials, where it is designed to specifically target soluble amyloid-beta oligomers. The firm was established in 1996 and maintains its principal headquarters in Charlottesville, Virginia.
Latest quote
$2.92
+$0.06 · +2.10%
After-hours
$2.93
+$0.01 · +0.34%
Sep 11, 6:21 PM ET
Regular session · ET · Market data may be delayed.
Acumen Pharmaceuticals Inc. operates as a biopharmaceutical entity in the clinical development stage, dedicated to discovering and advancing therapeutic solutions for Alzheimer's disease. A key focus for the company involves progressing ACU193, an investigational targeted immunotherapy drug candidate. This particular humanized monoclonal antibody is currently undergoing initial human testing in Phase I clinical trials, where it is designed to specifically target soluble amyloid-beta oligomers. The firm was established in 1996 and maintains its principal headquarters in Charlottesville, Virginia.
Day range
Current $2.92
52-week range
Current $2.92
Regular session · ET · Market data may be delayed.
GoAI Score
Sell
Valuation
30
Expensive
Sentiment
55
Mixed
Risk
51
Elevated Risk
Momentum
57
Neutral
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
Acumen Pharmaceuticals Inc. operates as a biopharmaceutical entity in the clinical development stage, dedicated to discovering and advancing therapeutic solutions for Alzheimer's disease. A key focus for the company involves progressing ACU193, an investigational targeted immunotherapy drug candidate. This particular humanized monoclonal antibody is currently undergoing initial human testing in Phase I clinical trials, where it is designed to specifically target soluble amyloid-beta oligomers. The firm was established in 1996 and maintains its principal headquarters in Charlottesville, Virginia.
Day range
Current $2.92
52-week range
Current $2.92
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Cost of goods sold | — | — | — | — | 12.31M USD |
| Gross profit | — | — | — | — | −12.31M USD |
| Research and development | 104.89M USD | 93.8M USD | 42.32M USD | 32.36M USD | 12.31M USD |
| Selling, general, and administrative | 18.95M USD | 20.22M USD | 18.82M USD | 12.88M USD | 7.28M USD |
| Operating expenses | 123.83M USD | 114.02M USD | 61.14M USD | 45.24M USD | 7.28M USD |
| Interest income | 7.45M USD | 14.32M USD | 10.79M USD | 2.39M USD | 84K USD |
| Interest expense | 4.22M USD | 4.07M USD | 581K USD | — | — |
| Depreciation and amortization | 184K USD | 178K USD | 184K USD | 169K USD | 4K USD |
| Operating income | −123.83M USD | −114.02M USD | −61.14M USD | −45.24M USD | −19.58M USD |
| Net income | −121.34M USD | −102.33M USD | −52.37M USD | −42.86M USD | −100.61M USD |
Company facts updated Sep 11, 2026.
Recent quarterly results
Third-party consensus; not a GoAI recommendation.
Average target
$7.00
139.73% upsideFunds reporting this stock among their holdings, ordered by reported position size.
iShares Russell 2000 ETFIWM2.88M0.00%77.55B USD0.19%$288.89+0.41%
Vanguard Morningstar Total Stock Market ETFVTI2.4M0.00%2.3T USD0.03%$376.31+0.82%
iShares Russell 2000 Value ETFIWN1.22M0.01%14.28B USD0.24%$219.69+0.33%
Vanguard Extended Market ETFVXF1.1M0.00%93.7B USD0.05%$237.76+0.68%
Vanguard Russell 2000 ETFVTWO568.84K0.00%17.4B USD0.06%$116.76+0.36%
iShares Micro-Cap ETFIWC449.12K0.03%1.44B USD0.60%$190.84+0.39%
Dimensional - US Small Cap ETFDFAS286.04K0.00%15.39B USD0.26%$80.52+0.64%
Avantis U.S. Small Cap Equity ETFAVSC111.04K—3.07B USD0.25%$71.48+0.53%iShares Russell 2000 ETFIWMVanguard Morningstar Total Stock Market ETFVTIiShares Russell 2000 Value ETFIWNVanguard Extended Market ETFVXFVanguard Russell 2000 ETFVTWOiShares Micro-Cap ETFIWCDimensional - US Small Cap ETFDFASAvantis U.S. Small Cap Equity ETFAVSCAI-generated and delayed market data for informational and educational purposes only. Not investment advice.
